Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Ngi b bnh gan
In November 2023, AstraZeneca and Eccogene signed an exclusive license agreement for ECC5004, an investigational oral once-daily GLP-1RA for treating obesity, type 2 diabetes, and other cardiometabolic conditions
6.3 Clinical applications in cardiovascular disease prevention Recent American College of Cardiology/American Heart Association guidelines advocate for the use of GLP-1RAs in patients with T2DM at high risk of atherosclerotic cardiovascular disease (ASCVD), irrespective of well-controlled glucose levels, based on the clinical trials mandated by FDA-issued industry guidelines in December 2008 to assess the cardiovascular effects of new diabetic therapies (247)
Patients with PCOS may experience: reproductive abnormalities inflammation correlated with insulin resistance irregular or absent menstrual periods excess androgens (male hormones such as testosterone) polycystic ovaries resulting from the hormonal imbalances hirsutism (male-patterned hair growth) acne alopecia (thinning or loss of scalp hair) Additionally, both reproductive-age and older women with PCOS have an increased risk for conditions such as: impaired glucose tolerance type 2 diabetes mellitus elevated cholesterol or lipids increased abdominal adiposity obesity hypertension metabolic syndrome depression anxiety obstructive sleep apnea nonalcoholic fatty liver disease endometrial cancer cardiovascular disease Research suggests that medication alone might not be enough to address PCOS
US$ 22.17
US$ 21.81
US$ 27.13
US$ 27.41
